With multiple pathways and stakeholders involved, there needs to be an arbiter who decides what is the highest quality and highest value care in oncology, said Lucy Langer, MD, MSHS, national medical director, oncology and genomics, UnitedHealthcare.
With multiple pathways and stakeholders involved, there needs to be an arbiter who decides what is the highest quality and highest value care in oncology, said Lucy Langer, MD, MSHS, national medical director, oncology and genomics, UnitedHealthcare.
Transcript
When looking at value-based care, who should decide what value really is?
One of the things I'm going to talk about this evening is drug pathways. There are many drug pathways out there. There are provider pathways, there are payer pathways, and then there's the NCCN [National Comprehensive Cancer Network] preferred pathways. And they're all different.
They do have areas of overlap, but they're all different. And when 3 major players in the health system and in oncology can't agree on pathways, at some point, you have to decide who's the ultimate arbiter of the pathways and decide: are we going to go with that group's pathways to help promote highest quality, highest value care? We're going to talk about that a little bit. I think it raises more questions than answers.
My personal philosophy is that the practicing oncologist should be the one who determines what's best for the patient. For groups like Rocky Mountain Cancer Centers, who are hosting tonight's event, I have no qualms whatsoever about them being the arbiter of what's best. But in my role at UnitedHealthcare—having been in this seat now for a year—I can say the variability in quality and integrity in selection of regimens is vast across the United States.
While here in Colorado, we may not have so much of an issue, from a national perspective, we're trying to thread that needle and figure out how do we best promote highest quality care for value contracting.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More